Hikma Pharmaceuticals/£HIK
07:00
09:10
11:15
13:25
15:30
1D1W1MYTD1Y5YMAX
About Hikma Pharmaceuticals
Hikma Pharmaceuticals is a multinational pharmaceutical company headquartered in London, United Kingdom. It specializes in the development, manufacturing, and marketing of a broad portfolio of branded and non-branded generic and in-licensed pharmaceutical products. The company operates across three main segments: Injectables, Generics, and Branded, serving hospitals, pharmacies, and wholesalers. Hikma was founded in 1978 in Amman, Jordan, and has since expanded its operations globally, maintaining a significant presence in the Middle East and North Africa, the United States, and Europe. Its strategic positioning is supported by its extensive manufacturing capabilities and a strong commitment to quality and regulatory compliance.
Ticker
£HIK
Sector
Primary listing
LSE
Industry
Pharmaceuticals
Headquarters
Employees
9,500
Website
HIK Metrics
BasicAdvanced
£4.5B
16.95
£1.19
0.45
£0.60
2.98%
Price and volume
Market cap
£4.5B
Beta
0.45
52-week high
£23.60
52-week low
£17.51
Average daily volume
392K
Dividend rate
£0.60
Financial strength
Current ratio
1.144
Quick ratio
0.587
Long term debt to equity
28.134
Total debt to equity
56.269
Dividend payout ratio (TTM)
48.75%
Interest coverage (TTM)
6.39%
Profitability
EBITDA (TTM)
567.706
Gross margin (TTM)
45.25%
Net profit margin (TTM)
11.48%
Operating margin (TTM)
19.00%
Effective tax rate (TTM)
20.44%
Revenue per employee (TTM)
£244,570
Management effectiveness
Return on assets (TTM)
7.74%
Return on equity (TTM)
15.98%
Valuation
Price to earnings (TTM)
16.946
Price to revenue (TTM)
1.931
Price to book
1.94
Price to tangible book (TTM)
3.87
Price to free cash flow (TTM)
18.354
Free cash flow yield (TTM)
5.45%
Free cash flow per share (TTM)
110.16%
Dividend yield (TTM)
2.98%
Growth
Revenue change (TTM)
8.77%
Earnings per share change (TTM)
89.41%
3-year revenue growth (CAGR)
6.99%
10-year revenue growth (CAGR)
7.70%
3-year earnings per share growth (CAGR)
-3.77%
10-year earnings per share growth (CAGR)
1.48%
3-year dividend per share growth (CAGR)
14.00%
10-year dividend per share growth (CAGR)
13.78%
What the Analysts think about HIK
Analyst ratings (Buy, Hold, Sell) for Hikma Pharmaceuticals stock.
Bulls say / Bears say
Hikma Pharmaceuticals plans to invest $1 billion by 2030 to expand its U.S. manufacturing and R&D capabilities, enhancing its production capacity and potentially increasing market share. (prnewswire.com)
The company has acquired the FDA-approved ANDA for trametinib tablets, securing 180 days of U.S. generic market exclusivity, which could boost revenue in the oncology segment. (prnewswire.com)
Hikma reported a 19% increase in core operating profit for 2023, driven by strong performance in its generics business, indicating robust financial health. (reuters.com)
Hikma forecasts a slight decline in profit for 2024, projecting a core operating profit between $660 million and $700 million, compared to $707 million in 2023. (reuters.com)
The company's total liabilities increased by 13.8% in 2024, reaching $2.812 billion, which may raise concerns about its debt levels. (barchart.com)
Hikma's operating cash flow decreased by 23.47% in 2024, indicating potential challenges in cash generation. (barchart.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Jul 2025.
HIK Financial Performance
Revenues and expenses
HIK Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Hikma Pharmaceuticals stock?
Hikma Pharmaceuticals (HIK) has a market cap of £4.5B as of July 26, 2025.
What is the P/E ratio for Hikma Pharmaceuticals stock?
The price to earnings (P/E) ratio for Hikma Pharmaceuticals (HIK) stock is 16.95 as of July 26, 2025.
Does Hikma Pharmaceuticals stock pay dividends?
Yes, the Hikma Pharmaceuticals (HIK) stock pays dividends to shareholders. As of July 26, 2025, the dividend rate is £0.60178 and the yield is 2.98%. Hikma Pharmaceuticals has a payout ratio of 48.75% on a trailing twelve-month basis.
When is the next Hikma Pharmaceuticals dividend payment date?
The next Hikma Pharmaceuticals (HIK) dividend payment date is unconfirmed.
What is the beta indicator for Hikma Pharmaceuticals?
Hikma Pharmaceuticals (HIK) has a beta rating of 0.45. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.